WUXI BIO (02269) has announced a resolution to utilize the general mandate granted by its shareholders at the Annual General Meeting held on June 6, 2025, for the repurchase of the company's shares. Under this buyback authorization, the company is permitted to repurchase up to 407 million shares on The Stock Exchange of Hong Kong Limited, representing 10% of the total issued shares as of the date of the Annual General Meeting. On May 24, 2026, the company resolved to implement this authorization and, where applicable, any future general mandates approved by shareholders at general meetings for share repurchases, to buy back shares in the open market from time to time with a total consideration not exceeding US$400 million (the Proposed Share Buyback).